Related Experiment Video
Updated: Aug 10, 2026

Examination of Mitotic and Meiotic Fission Yeast Nuclear Dynamics by Fluorescence Live-cell Microscopy
Published on: June 24, 2019
Recombination and hydroxyurea inhibition of DNA synthesis in yeast meiosis
Abstract:
Hydroxyurea (HU) inhibits the premeiotic DNA replication and the meiotic events that followed, namely readiness, recombination commitment, haploidisation, sporulation commitment and ascus formation. Short incubations with HU (2-4 hrs) during the premeiotic replication (i.e. starting between 3 and 6.5 hrs in sporulation medium) allow the resumption of the replication at a normal rate following the removal of the drug. The other meiotic events are similarly delayed by the approximate length of the treatment. In these experiments, intragenic recombination in ade2 reached a higher level than in the controls (x 1.3-2.0 in one pair of heteroalleles and x 3.0-4.0 in another pair). The recombination response to short HU treatments was not observed for a pair of heteroalleles in ade2 that normally shows a high level of meiotic recombination (750 per 10(6) cells), nor was the response observed in a pair of heteroalleles in lys2. HU treatments have almost no effect on sporulating cells from 8 hrs onwards. At 7-7.5 hrs the meiotic cells are very sensitive to the drug and even short treatments cause cell death and massive DNA degradation.
Insights
Hydroxyurea (HU) treatment during yeast premeiotic DNA replication delays meiosis and increases intragenic recombination. However, HU is toxic to cells treated late in meiosis.
Area of Science:
- Molecular Biology
- Genetics
- Cell Biology
Background:
- Meiosis is a fundamental process for sexual reproduction, involving DNA replication and recombination.
- Hydroxyurea (HU) is a known inhibitor of DNA replication.
Purpose of the Study:
- To investigate the effects of short hydroxyurea (HU) treatments on meiotic DNA replication and recombination in yeast.
- To determine the optimal timing for HU treatment to modulate meiotic events without causing toxicity.
Main Methods:
- Yeast cells were treated with hydroxyurea (HU) at different time points during the premeiotic S phase.
- DNA replication rates, meiotic progression, and intragenic recombination frequencies were analyzed after HU removal.
- Sensitivity of meiotic cells to HU at different stages was assessed.
Main Results:
- Short HU treatments during premeiotic replication delayed meiotic progression but allowed normal replication resumption upon drug removal.
- Intragenic recombination frequencies increased significantly in some ade2 heteroalleles following HU treatment.
- HU treatments late in meiosis (7-7.5 hrs) were toxic, causing cell death and DNA degradation.
- No enhanced recombination was observed for high-recombination heteroalleles or in lys2 mutants.
Conclusions:
- Hydroxyurea (HU) can be used to transiently inhibit premeiotic DNA replication, leading to delayed meiosis and enhanced intragenic recombination.
- The timing of HU treatment is critical, as late-stage treatments are detrimental to cell viability.
- The observed recombination enhancement is allele-specific and dependent on the basal recombination rate.
More Related Videos
Related Concept Videos
Crossing Over
The homologous pairs of sister chromosomes—one from the maternal and one from the paternal genome—then begin to align alongside each other lengthwise, matching corresponding DNA positions in a process called synapsis.
In order to...
Homologous Recombination
Gene Conversion
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Homologous Recombination
Crossing Over

